Precautions during use of anifrolumab

Anilumab (anifrolumab), as an innovative biological agent for moderate to severe systemic lupus erythematosus (SLE), brings new treatment hope to patients. However, before receiving anilumab treatment, both patients and physicians need to fully understand and follow a series of important precautions to ensure the safety and effectiveness of the treatment.

First, anilumab is absolutely contraindicated in patients who are allergic to the active ingredient in the injectionanirolumab-fnia or any of the inactive ingredients. Therefore, before receiving treatment, it is important for patients to provide their doctor with a complete allergy history and carefully review the drug's ingredient list to avoid unnecessary allergic reactions.

In addition, patients should inform their physicians in detail about all of their medical conditions before starting treatment with anilumab, especially regarding infections, cancer, and other treatments they are receiving. If a patient has an infection or a recurring infection, he should avoid treatment with anilumab unless specifically directed by his doctor, as the drug may reduce the immune system's resistance and increase the risk of infection.

For patients who have or have had any type of cancer, while using anilumab, if the patient is receiving other biological drugs or monoclonal antibody treatments, they must also inform their doctor in advance to avoid drug-drug interactions and potential adverse reactions.

Patients should also ensure that all necessary vaccinations are completed before starting treatment with anilumab. However, patients should avoid receiving live vaccines during treatment because anilumab may affect immune system function, reduce vaccine effectiveness or increase the risk of adverse reactions.

The use of anilumab also requires special consideration in patients who are pregnant or planning pregnancy. While it's not known whether the drug will cause harm to an unborn baby, having SLE during pregnancy can cause a range of complications. Therefore, patients should fully communicate with their doctors to weigh the benefits of treating SLE against the possible risks to the baby and make informed decisions.

In short, before receiving anilumab treatment, patients need to fully communicate and evaluate with their doctors to ensure that they understand all possible risks and precautions, and follow the doctor's recommendations for treatment.

Reference link: https://www.drugs.com/anifrolumab.html